|
Synonyms: MOXR 0916 | MOXR0916 | pogalizumab (deleted INN) | RG7888 | RO7021608
Compound class:
Antibody
Comment: Vonlerolizumab (MOXR0916) was an investigational humanized anti-human OX40 monoclonal, with reported preclinical efficacy [1]. Genentech terminated their Phase 2 trial NCT03029832 and have discontinued further development.
|
| References |
|
1. Huseni M, Totpal K, Du C, Dalpozzo K, Zhu J, Rishipathak D, McNamara E, Jonshtone B, Hegde PS, Rhee I. (2014)
Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models. Journal for Immunotherapy of Cancer, 2 (Suppl 3): 105. |
